Manufactures and sells medical devices, including breathing equipment and masks, to medical institutions and distributors.
20-F for FY2025, filed Jan 30, 2026
Customers buy the subsidiaries’ self-manufactured medical devices and masks; credit customers may have 30 to 180 days to pay, and sales are completed when products are delivered. Commodity trading also involves delivering products to customers.
20-F for FY2025, filed Jan 30, 2026The Group grants credit sales for customers and the credit period varies among different customers. The Group normally grants the customers…View ↗
The Group identifies one performance obligation in this business, which is to transfer control of a product to a distributor customer or…View ↗
The Group identifies one performance obligation in commodity trading, which is to transfer control of a product to a customer upon delivery…View ↗
20-F for FY2025, filed Jan 30, 2026
FY2025 revenue by product or service ↗$9.8M
20-F for FY2025, filed Jan 30, 2026
$9.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Medical Devices Other than Masks
Sold outright
20-F for FY2025, filed Jan 30, 2026 |
93%
FY2022: 44%
|
Medical Devices Other than Masks, FY2025
$9.1M Sources
|
Sold outright |
|
Masks
Sold outright
|
6.5%
FY2022: 54%
|
Masks, FY2025
$640.4K Sources
|
Sold outright |
|
Commodity Trading
Sold outright
|
0.6%
FY2022: 0.5%
|
Commodity Trading, FY2025
$55.4K Sources
|
Sold outright |
|
Others
|
0.2%
FY2022: 1.2%
|
Others, FY2025
$18.5K Sources
|
Hospitals, pharmacies and other medical institutions buy directly; domestic and export distributors buy products for resale to end users. Sales run through the subsidiaries’ sales team and distributor network.
20-F for FY2025, filed Jan 30, 2026
Not on paper. It lost $1.1M in FY2025, but brought in more cash than it spent: $4.9M of free cash flow.
20-F for FY2025, filed Jan 30, 2026
−$2.5MView ↗
20-F for FY2025, filed Jan 30, 2026
−$1.1MView ↗
20-F for FY2025, filed Jan 30, 2026
$4.9MView ↗
Loading...